Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexapro

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

Baxter to cut 400 jobs in Puerto Rico

Plans to shift operations to the Dominican Republic

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Lundbeck’s alcohol dependency drug approved in Europe

Selincro is the first drug approved to reduce alcohol consumption

- PMLiVE

Fitness first: How pharma can get in shape for the future

As the market changes, existing capabilities become useless and new ones become essential. Professor Brian D Smith describes how pharma companies become fit for the future

- PMLiVE

Abbott and GSK announce job cuts in Ireland

Nearly 300 positions to go in Cork and Tipperary

- PMLiVE

Former Nycomed CEO Hakan Bjorklund to chair Lundbeck

Mats Pettersson to step down in March

- PMLiVE

Lundbeck looks to new products as Lexapro slumps

Denmark-based pharma company reports flat sales during fourth quarter of 2012

- PMLiVE

GSK planning restructuring in Europe as earnings fall

Includes job cuts and potential sale of Ribena/Lucozade brands

- PMLiVE

Merck & Co shares fall on Q4 results, osteoporosis drug delay

Sales down on loss of patent protection for Singulair

- PMLiVE

New products help Lilly achieve flat Q4 sales

Effient and Alimta counter patent expiry to Zyprexa

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links